Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to demonstrate equivalent efficacy and similarity in the safety
profile of GP2017 and Humira® in patients with moderate to severe chronic plaque-type
psoriasis.